News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
A study published in the Journal of Clinical Oncology presents findings from the PREDICT trial, which evaluated ultrasensitive circulating tumor DNA (ctDNA) as a tool for detecting minimal residual disease (MRD) in breast cancer patients. The research demonstrates the potential of liquid biopsy-based ctDNA assays to identify residual cancer cells that remain after treatment, which could help clini…
[Articles] Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study
A large-scale global modelling study published in The Lancet projects that worldwide inequalities in cervical cancer incidence and mortality will increase dramatically unless HPV vaccination and screening efforts are substantially enhanced. The researchers found that achieving the WHO elimination targets for vaccination and screening coverage, or introducing universal HPV vaccination with high upt…
[Articles] Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
A landmark patient-level meta-analysis published in The Lancet, encompassing 15,000 premenopausal women across 23 randomised trials, has demonstrated that ovarian function suppression (OFS) significantly reduces the 15-year risk of breast cancer recurrence and death in ER-positive early breast cancer. The benefit persisted even in women already receiving chemotherapy or tamoxifen, strengthening th…
[Articles] CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
A large reconstructed individual patient data meta-analysis of phase 3 randomized trials published in The Lancet Oncology confirms that adding CDK4/6 inhibitors to endocrine therapy significantly improves both progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer. Crucially, the analysis reveals clinically meaningful differe…
[Articles] Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers
A comprehensive simulation-based study published in The Lancet Oncology has modeled both total and diagnosed cancer incidence across 17 cancer types worldwide from 1990 to 2050. The analysis reveals a substantial and growing global cancer burden, with particularly alarming gaps in low- and middle-income countries where many patients die without ever receiving a diagnosis. By integrating demographi…
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research
A comprehensive review published in Nature Reviews Cancer examines how artificial intelligence can be leveraged to integrate multi-omics data — including genomics, transcriptomics, proteomics, and metabolomics — to unlock deeper insights into cancer biology and treatment response. Liu and colleagues argue that analyses limited to a single omics layer risk missing critical dimensions of biological …
Blood test hints at breast-tumour response to treatment
Researchers have identified a blood-based biomarker that can predict which patients with certain types of breast cancer are more likely to respond to immune-based therapy, according to a study highlighted by Nature. The finding could help clinicians personalize immunotherapy decisions, sparing non-responders from ineffective treatment and its associated side effects. Predictive biomarkers for immu…
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
A phase III randomized noninferiority trial (neoCARHP), published in the Journal of Clinical Oncology, investigated whether carboplatin can be safely omitted from the neoadjuvant regimen of taxane plus trastuzumab and pertuzumab in patients with HER2-positive breast cancer. The trial addresses a critical clinical question about treatment de-escalation, aiming to reduce the well-known toxicity burd…
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603
The Journal of Clinical Oncology has published the long-term results of JCOG0603, a landmark Japanese randomized Phase II/III trial evaluating whether adding adjuvant mFOLFOX6 chemotherapy after liver resection improves outcomes for patients with colorectal cancer liver metastases compared to surgery alone. This trial addresses a longstanding clinical question, as the role of adjuvant chemotherapy…
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
The Journal of Clinical Oncology has published the HER2CLIMB-05 trial, a Phase III randomized study evaluating the addition of tucatinib to the standard first-line backbone of trastuzumab and pertuzumab as maintenance therapy in HER2-positive metastatic breast cancer. Tucatinib is a highly selective oral HER2-targeted tyrosine kinase inhibitor already approved for later-line HER2-positive disease …